Vitamin D receptor activator and prevention of cardiovascular events in hemodialysis patients—rationale and design of the Japan Dialysis Active Vitamin D (J-DAVID) trial

[1]  M. Tonelli,et al.  Association of Drug Effects on Serum Parathyroid Hormone, Phosphorus, and Calcium Levels With Mortality in CKD: A Meta-analysis. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[2]  K. Iseki,et al.  Use of Vitamin D Receptor Activator, Incident Cardiovascular Disease and Death in a Cohort of Hemodialysis Patients , 2015, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[3]  A. Go,et al.  Fibroblast growth factor-23 and cardiovascular events in CKD. , 2014, Journal of the American Society of Nephrology : JASN.

[4]  C. Lam,et al.  Effect of paricalcitol on left ventricular mass and function in CKD--the OPERA trial. , 2014, Journal of the American Society of Nephrology : JASN.

[5]  Takayuki Hamano,et al.  Overview of Regular Dialysis Treatment in Japan (as of 31 December 2011) , 2013, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[6]  M. Dorgan,et al.  Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis , 2013, The Lancet.

[7]  K. Iseki,et al.  Clinical Practice Guideline for the Management of Chronic Kidney Disease‐Mineral and Bone Disorder , 2013, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[8]  K. Iseki,et al.  Serum Phosphate and Calcium Should Be Primarily and Consistently Controlled in Prevalent Hemodialysis Patients , 2013, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[9]  K. Mahaffey,et al.  Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. , 2012, The New England journal of medicine.

[10]  Onyebuchi A Arah,et al.  Administered paricalcitol dose and survival in hemodialysis patients: A marginal structural model analysis , 2012, Pharmacoepidemiology and drug safety.

[11]  L. Hsiao,et al.  Vascular Klotho Deficiency Potentiates the Development of Human Artery Calcification and Mediates Resistance to Fibroblast Growth Factor 23 , 2012, Circulation.

[12]  S. Solomon,et al.  Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. , 2012, JAMA.

[13]  T. Abe,et al.  Chronic kidney disease, dyslipidemia, and atherosclerosis. , 2012, Journal of atherosclerosis and thrombosis.

[14]  A. Go,et al.  FGF23 induces left ventricular hypertrophy. , 2011, The Journal of clinical investigation.

[15]  E. Seibert,et al.  Vitamin D Deficiency, Mortality, and Hospitalization in Hemodialysis Patients with or without Protein-Energy Wasting , 2011, Nephron Clinical Practice.

[16]  K. Iseki,et al.  Elevated non-high-density lipoprotein cholesterol (non-HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[17]  A. Vaglio,et al.  Increased fetuin-A levels following treatment with a vitamin D analog. , 2010, Kidney international.

[18]  D. Prié,et al.  Reciprocal control of 1,25-dihydroxyvitamin D and FGF23 formation involving the FGF23/Klotho system. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[19]  R. Pratt,et al.  Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy , 2009, Current medical research and opinion.

[20]  M. Wolf,et al.  Phosphorus binders and survival on hemodialysis. , 2009, Journal of the American Society of Nephrology : JASN.

[21]  R. Wolfe,et al.  The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[22]  CaCO,et al.  Clinical Practice Guideline for the Management of Secondary Hyperparathyroidism in Chronic Dialysis Patients , 2008, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[23]  K. Wakai,et al.  Overview of Regular Dialysis Treatment in Japan as of 31 December 2006 , 2008, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[24]  D. Rodríguez‐Puyol,et al.  Oral active vitamin D is associated with improved survival in hemodialysis patients. , 2008, Kidney international.

[25]  M. Wolf,et al.  Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. , 2008, The New England journal of medicine.

[26]  Z. Massy,et al.  Vitamin D levels and early mortality among incident hemodialysis patients. , 2008, Kidney international.

[27]  K. Kalantar-Zadeh,et al.  Vitamin D receptor activation and survival in chronic kidney disease. , 2008, Kidney international.

[28]  C. Wanner,et al.  A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. , 2008, Kidney international.

[29]  K. Iseki,et al.  Effects of Serum Calcium, Phosphorous, and Intact Parathyroid Hormone Levels on Survival in Chronic Hemodialysis Patients in Japan , 2008, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[30]  W. Suki,et al.  Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. , 2007, Kidney international.

[31]  N. Bodyak,et al.  Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals , 2007, Proceedings of the National Academy of Sciences.

[32]  A. Levin,et al.  Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. , 2007, Kidney international.

[33]  M. Budoff,et al.  Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. , 2006, Kidney international.

[34]  G. Eknoyan,et al.  Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). , 2006, Kidney international.

[35]  J. Adams,et al.  1,25‐Dihydroxyvitamin D3 inhibits lipopolysaccharide‐induced immune activation in human endothelial cells , 2006 .

[36]  J. Adams,et al.  1,25-Dihydroxyvitamin D inhibits lipopolysaccharide-induced immune activation in human endothelial cells. , 2006, Clinical and experimental immunology.

[37]  M. Hernán,et al.  Activated injectable vitamin D and hemodialysis survival: a historical cohort study. , 2005, Journal of the American Society of Nephrology : JASN.

[38]  G. Chertow,et al.  Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. , 2004, Journal of the American Society of Nephrology : JASN.

[39]  S. Fukumoto,et al.  Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[40]  R. Wolfe,et al.  Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). , 2003, Journal of the American Society of Nephrology : JASN.

[41]  Bertram L Kasiske,et al.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Hypertension.

[42]  Shu Q. Liu,et al.  1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system , 2002 .

[43]  H. Koyama,et al.  Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. , 2002, Journal of the American Society of Nephrology : JASN.

[44]  Shu Q. Liu,et al.  1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. , 2002, The Journal of clinical investigation.

[45]  P. Stenvinkel,et al.  Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[46]  C. G. Bellows,et al.  Expression of mRNAs for type-I collagen, bone sialoprotein, osteocalcin, and osteopontin at different stages of osteoblastic differentiation and their regulation by 1,25 dihydroxyvitamin D3 , 1999, Cell and Tissue Research.

[47]  L. Cook,et al.  Modulation of bone morphogenetic protein-2 and bone morphogenetic protein-4 gene expression in osteoblastic cell lines. , 1998, Cellular and molecular biology.

[48]  S. Otani,et al.  Effect of 1,25‐dihydroxyvitamin D3 on induction of scavenger receptor and differentiation of 12‐O‐tetradecanoylphorbol‐13‐acetate‐treated THP‐1 human monocyte like cells , 1995, Journal of cellular physiology.

[49]  T. Tabata,et al.  The effect of 1 alpha-hydroxyvitamin D3 on cell-mediated immunity in hemodialyzed patients. , 1986, The Journal of clinical endocrinology and metabolism.